𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Scribed by Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
286 KB
Volume
32
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg.

Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (53%) responders to this agent. Periods of remission ranged from 5-26 months with a median of 10 and a mean of 12 + months.

Higher rates of response were noted in women over 50 years of age, in patients with osseous metastasis, and in patients with a longer disease-free interval. Adverse effects included weight gain, Cushingoid appearance, skin rash, and vaginal discharge. In this selected group of patients, oral medroxyprogesterone at a dose level of 400 mglday appeared to provide a significant frequency of tumor response.

πŸ“œ SIMILAR VOLUMES

Clinical trial of high-dose oral medroxy
Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature
✍ Enrique Davila; Charles L. Vogel; Dawn East; Victoria Cairns; Susan Hilsenbeck πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 696 KB

Recent studies have suggested that there are benefits from the use of high-dose parenteral medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer. The present study was designed to assess the efficacy and toxicity of high-dose oral MPA in women with clinical parameters sugges

Pharmacokinetic and pharmacodynamic basi
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate
✍ Hans Christian Blossey; Hans Erik Wander; Johannes Koebberling; Professor Dr. Ge πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 728 KB

Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day. The relation of MPA plasma concentrations and endocrine effects were studied in a longitudinal fashion. MPA exerted suppressive effe

Cyclic and sequential therapy with tamox
Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer
✍ Takuma Nemoto; Dr. Jashbhai K. Patel; Dutzu Rosner; Thomas L. Dao; H. Halvorson πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 262 KB

A clinical trial of sequential tamoxifen and medroxyprogesterone acetate (MPA) was carried out in 36 women with metastatic breast cancer in order to evaluate the therapeutic efficacy of this regimen and to determine if tamoxifen would increase progesterone receptor (PR) levels and thereby increase r